Pharmaceuticals, Biotechnology and Life Sciences
BURLINGAME, Calif.–(BUSINESS WIRE)–Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™,…
ST. LOUIS, Mo.–(BUSINESS WIRE)–M6P Therapeutics, a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), today announced its support for Rare Disease Day 2021 and…
LAUSANNE, Switzerland–(BUSINESS WIRE)–ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for pat…
HEMEL HEMPSTEAD, England & BURLINGTON, Mass.–(BUSINESS WIRE)–EUSA Pharma (UK) Limited (“EUSA Pharma”), a global biopharmaceutical company focused on oncology and rare diseases, announced that the National Comprehensive Cancer Network® (NCCN®) has upd…
ReForm Biologics Expands Focus to Develop In-house Pipeline of Bio-innovative Medicines
WOBURN, Mass.–(BUSINESS WIRE)–ReForm Biologics today announced it will expand its focus to develop a new generation of bio-innovative biologic medicines in-house…
CTP-543 Phase 3 Program Advancing in Alopecia Areata; THRIVE-AA2, the Second CTP‑543 Phase 3 Trial, to Initiate 1H2021
CTP-543 Long-Term Data Presented at EADV Show Hair Regrowth was Maintained or Improved in Patients with Alopecia Areata, Expanding …
BOSTON & LOUISVILLE, Ky.–(BUSINESS WIRE)–Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care…
— Achieved Favorable Clinical Results Across Four First-in-Class Gene Therapy Programs for Danon Disease, FA, LAD-I and PKD —
— Announced >50% Protein Expression with Stabilization and Biomarker Improvement Including Cardiac Output in Low Dose Coh…
— Launched EYSUVIS™, First and Only Prescription Therapy Approved Specifically for Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease —
— Progressing Pipeline Programs to Address Front and Back of Eye Diseases —
— Cash Position a…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–$AVRO–AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are sched…